{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-22-000190","form_type":"8-K","ticker":"SRZN","cik":"0001824893","company_name":"Surrozen, Inc./DE","filed_at":"2022-01-10T23:59:59+00:00","discovered_at":"2026-05-14T18:04:08.567900+00:00","generated_at":"2026-06-27T19:35:18.893657+00:00","sec_items":["8.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Surrozen expects to start Phase 1 trials for SZN-1326 and SZN-043 in Q3 2022; nominates SZN-413 candidate","bullets":["Expects to initiate Phase 1 clinical trials of SZN-1326 and SZN-043 in Q3 2022.","Nominated SZN-413, a mono Fzd4 bi-specific antibody, for retinal vascular diseases including wet AMD and diabetic retinopathies.","None of the product candidates have been tested in humans or gained regulatory approval."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-22-000190","json":"https://secwatch.observer/filing/0000950170-22-000190.json","markdown":"https://secwatch.observer/filing/0000950170-22-000190.md","text":"https://secwatch.observer/filing/0000950170-22-000190.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1824893/000095017022000190/0000950170-22-000190-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1824893/000095017022000190/srzn-20220110.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-27T19:35:18.893657+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}